Trial Profile
A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and correlative science studies attempting to identify predictors of response A phase II, open label, single arm trial of neoadjuvant therapy in patients with triple negative breast cancer evaluating the efficacy of eribulin mesylate following anthracycline and taxane and correlative science studies attempting to identify predictors of response
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 23 Feb 2018
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Taxanes (Primary) ; Anthracyclines
- Indications Breast cancer
- Focus Therapeutic Use
- Acronyms HOPE
- 23 Feb 2018 Status changed from suspended to discontinued.
- 12 Oct 2017 Primary Endpoint (Pathological complete response (pCR) rate) has been not met, according to results presented at the 42nd European Society for Medical Oncology Congress.
- 11 Oct 2017 New trial record